These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18081622)

  • 1. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
    Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
    Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
    Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
    N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
    Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.
    Rainer M; Haushofer M; Pfolz H; Struhal C; Wick W
    Eur Psychiatry; 2007 Sep; 22(6):395-403. PubMed ID: 17482432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
    Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
    Yoon HJ; Park KM; Choi WJ; Choi SH; Park JY; Kim JJ; Seok JH
    BMC Psychiatry; 2013 Sep; 13():240. PubMed ID: 24074357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine.
    Savaskan E; Schnitzler C; Schröder C; Cajochen C; Müller-Spahn F; Wirz-Justice A
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):507-16. PubMed ID: 16316485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
    Gareri P; Cotroneo A; Lacava R; Seminara G; Marigliano N; Loiacono A; De Sarro G
    Arch Gerontol Geriatr Suppl; 2004; (9):207-15. PubMed ID: 15207416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
    Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
    J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
    Johnsen E; Kroken RA; Wentzel-Larsen T; Jørgensen HA
    BMC Psychiatry; 2010 Mar; 10():26. PubMed ID: 20334680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.